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Abstract The occurrence of hPTH-1-37 as the native bioactive 
circulating form of PTH-1 84 has now been obtained using a 
specific purification procedure for circulating parathyroid 
hormone, which involves a newly developed immunoenzymetric 
assay for N-terminally intact hPTH. In combination with two 
different methods of mass spectrometry, the molecular weight of 
the isolated immunoreactive peptide was shown to be 4401 Da, 
which corresponds to hPTH-1-37. Synthetic hPTH-1-37 
material was tested in the chick bioassay and produced a clear-
cut increase in serum calcium concentration. We conclude that 
hPTH-1-37 is the native bioactive fragment of hPTH-1-84 in 
circulation. 
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1. Introduction 
Parathyroid hormone (PTH) is synthesized in the chief cells 
of the parathyroid glands as part of the precursor molecule, 
prepro-PTH [1]. After cleavage of the prepro-sequence in the 
rough endoplasmic reticulum and Golgi apparatus, PTH is 
concentrated in dense-cored secretory vesicles. These vesicles 
fuse with the plasma membrane and PTH is released in re-
sponse to decreased serum calcium levels. Under physiological 
conditions, secretion occurs predominantly as the intact 
hPTH-1-84 molecule with a molecular weight of 9425 Da 
[2], and a minor fraction of hPTH was shown to be metabo-
lized prior to secretion. For human pathological parathyroid 
tissue, a Ca2+-dependent release of quantities of N-terminal 
PTH fragments about 3-6 times greater than those of intact 
hPTH-1-84 is described [3]. The molecular forms which were 
shown by immunoassays or by radioactive labeling experi-
ments to occur in the circulation [4,5] comprised mainly C-
terminal and midregional fragments [6]. The generally lower 
concentrations of circulating N-terminal fragments were ex-
plained by peritubular uptake of N-terminal PTH by the kid-
ney in addition to filtration [7,8] and selective uptake of N-
terminal PTH fragments by bone [9]. Canterbury et al. [10] 
found that bovine PTH-1-84 was metabolized to N-terminal 
fragments by rat liver. However, given the fact that in the 
majority of studies bovine PTH was tested in heterologous 
species and taking into account the scarce information per-
taining to man, the principal objective of the present investi-
gation was to identify the major bioactive hPTH fragment in 
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human hemofiltrate which would represent a valuable prepur-
ified source for the large-scale extraction of smaller circulating 
peptides [11]. RIA and ELISA measurements [12] showed 
concentrations of regulatory peptides similar to those ob-
served in plasma. Our earlier studies have shown that C-ter-
minal hPTH fragments can be isolated from human blood 
filtrate [13] and for this reason, we have extensively studied 
the probably most important natural bioactive N-terminal 
molecular form [14] circulating in human blood. This present 
paper gives more substantial evidence that hPTH-1-37 occurs 
in human blood, as is revealed by isolation with mass spec-
trometry and immunoenzymetric assay screening. 
2. Materials and methods 
2.1. Purification of parathyroid hormone 
Hemofiltrate was collected from patients with chronic renal failure 
and was obtained from a local dialysis center (Niedersachsisches Zen-
trum fur Nephrologie, Hannoversch-Miinden, Germany). During he-
mofiltration, a filter with a 20000 Da cut-off was used in order to 
reduce the amount of filtered large molecular proteins. 
The first step of purification was carried out with a modification 
[15] of the polypeptide isolation procedure described by Mutt [16]. 
After collection, hemofiltrate was immediately acidified with HC1 to 
pH 3.5. A 1000 liter batch was diluted 1:1 (v/v) with water, adjusted 
to pH 2.7 by adding concentrated HC1, and stirred for 12 h after 
addition of 2.5 kg alginic acid. The batch was then filtered on a 
Buchner funnel to obtain dry alginic acid with the absorbed peptides. 
The alginic acid was subsequently washed with 98% (v/v) ethanol to 
eliminate non-peptidergic substances from the binding matrix and 
0.005 N HC1. The polypeptides were then eluted with ice-cold 0.2 N 
HC1 and lyophilized (step 1). 
60 g of the extract obtained from 1000 1 of hemofiltrate was resus-
pended in 1000 ml of loading buffer (0.01 M phosphate buffer con-
taining 0.15 M sodium chloride, pH 7.2). The solution was filtered 
and applied to an affinity column (PerSeptiv, Sensor Cartridge XL, 
Wiesbaden, Germany) at a flow rate of 0.5 ml/min. 
For the preparation of the affinity column, a polyclonal antibody 
specific to the N-terminal residue of hPTH was first purified on EAH 
Sepharose (Pharmacia, Freiburg, Germany) to which hPTH-1-34 was 
covalently bound. The purified antibody was immobilized using the 
method described by Schneider et al. [17]. In brief, the Fc region of 
the antibody was bound to the protein G-coated matrix of the Sensor 
Cartridge XL affinity column. Subsequently, the F„b region was orien-
tated with dimethyl pimelimidate (DMP) in order to achieve the 
optimal antibody-antigen binding for separation of the hPTH-related 
material. After loading with the sample, the column was washed with 
loading buffer in order to obtain nonspecifically bound material, as 
controlled by optical density measurement at 215 nm. The column 
was then washed with eluting buffer (0.15 M sodium chloride, pH 
2.4) (step 2). The eluted immunoreactive peak was immediately trans-
ferred to a semipreparative reverse-phase (RP) C4 column (250 A, 20-
45 μηι, 20X150 mm, Parcosil, Biotek, Ostringen, Germany). The 
column was eluted using a continuous gradient starting with 10% 
acetonitrile and 0.1% TFA to 80%> acetonitrile and 0.1% TFA (step 
3). Fractions were identified by means of a two-site immunoenzy-
metric assay (IEMA) for N-terminal intact hPTH. The immunoreac-
tive fractions were pooled, diluted with water and directly applied to 
the next chromatographic step, performed with an analytical RP Cis 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / /S0014-5793 (9 6)01390-7 
222 
column (300 A, 5 μpiι, 4.6x250 mm, Vydac, Hesperia, CA, USA), 
using a gradient from 10% acetonitrile, 0.1% TFA to 60%) acetonitrile, 
0.1% TFA (Step 4). After this purification, all the fractions were 
determined by means of IEMA. 
2.2. Mass spectrometry 
Mass determination of fraction 24, which represents the highest 
activity in the IEMA, was carried out by two different methods. First, 
a combination of HPLC and mass spectrometry (LC-MS mode) was 
performed. LC/MS was conducted using an ABI 140A pump (Weiter-
stadt, Germany) to provide gradients with a flow rate of 20 μΐ/min. A 
microbore RP Ci8 YMC ODS-AQ (250X1 ID, 120 A, 3 urn, YMC, 
Wilmington, NC, USA) column was used and the gradient was 10% B 
to 70% B in 30 min (2%/min). Solvent A was 0.05% aqueous TFA and 
solvent B was water/acetonitrile/TFA (20:80:0.06). The column efflu-
ent was directed to a variable wavelength detector (750 A, ABI, Wei-
terstadt, Germany) set to monitor absorbance at 210 nm, and there-
after into a Sciex API III triple quadrupole mass spectrometer (Perkin 
Elmer, Sciex Instruments, Thornhill, Ont., Canada). The interface 
sprayer was operated at a positive potential of 5 kV. Positively 
charged ions were sampled in the analyzer region of the mass spectro-
meter through a 100 μηι orifice with an applied voltage of 60-100 V. 
Full scan single mass spectra were obtained by scanning quadrupole-1 
from 300 to 2400 m/z with a step size of 0.5 Da. A mixture of poly-
propylene glycols was used for mass calibration in the positive-ion 
module. Data were put into an Apple Macintosh computer and proc-
essed using the data analysis program MacSpec 3.1 (Sciex). 
For a second set of measurements, a matrix-assisted laser desorp-
tion/ionization (MALDI) time-of-flight mass spectrometer (LaserTec 
time-of-flight mass spectrometer, Vestec, Houston, TX, USA) was 
used in the positive-ion mode of detection. Samples were prepared 
by mixing 1.5 μΐ of the fraction possessing the highest immunological 
activity with 1.5 μΐ of saturated solution of oc-cyano-4-hydroxycin-
namic acid (as matrix) and applying the combined 3 μΐ to a stainless 
steel insertion probe tip. Preparations were allowed to air-dry before 
insertion into the vacuum system of the mass spectrometer. The time-
of-flight spectra were generated by a signal averaging 120 laser shots 
into a single spectrum and its transfer to an IBM-compatible personal 
computer. Spectra were calibrated using saturated ot-cyano-4-hy-
droxycinnamic acid as the matrix ion, and ubiquitin (MH+ 8565.9, 
MH2 + 4282.95) as the protein standard. 
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Fig. 1. Analytical reverse-phase HPLC profile on a Vydac-Ci8 col-
umn (250X4.6 mm ID). Solvent system: A: 0.1% TFA, B: 0.1% 
TFA in aqueous acetonitrile; flow rate 0.7 ml/min. Absorbance was 
measured at 210 nm. Crude extract of hemofiltrate purified by affin-
ity chromatography and applied twice to a semipreparative reverse-
phase column. IR-hPTH is found in fraction 24 only (see Fig. 2). 
40 45 
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Fig. 2. Immunoenzymetric assay (IEMA) from aliquots of the ana-
lytical RP HPLC fractions. The immunoreactivity of fraction 24 
represents hPTH-1-37. The minor activity at the end of the chroma-
tography derived from C-terminal-extended PTH fragments. 
2.3. Immunoenzymetric assay (IEMA) 
The IEMA procedure [18] was carried out in duplicate in microtiter 
plates (Maxisorb, Nunc, Wiesbaden, Germany). The wells were 
coated overnight with 0.5 μg/well of a monoclonal antibody. After 
the wells were washed, blocking buffer (0.05 M sodium carbonate 
buffer pH 9.4 with 1% gelatin) was added for 2 h to prevent nonspe-
cific binding. Thereafter, 100 μΐ sample or standard was added for 1 h. 
In the next step, 100 μΐ of the second antibody (a polyclonal antibody, 
purified by affinity chromatography; dilution 1:1000) was added for 
1 h. This antibody was marked with 100 μΐ AffiniPure anti-rabbit IgG-
POD at a dilution of 1:5000 (Dianova, Hamburg, Germany). The 
final step was the reaction with 100 μΐ substrate buffer (Boehringer 
Mannheim GmbH, Mannheim, Germany) containing 0.2 M ABTS 
(2,2'-azino-di-[3-ethylbenzthiazoline sulfonate] [6], Boehringer Mann-
heim, Mannheim, Germany) for 30 min and absorbance was meas-
ured at 405 nm. Between the various steps, extensive washing of the 
wells with buffer (PBS 0.015 M, 0.05% Tween 20) was performed. 
2.4. Bioassay 
The biological activity of hPTH-1-37 was tested in the chick bioas-
say [19] in terms of its ability to increase the serum calcium concen-
tration. Three different doses (1.0, 2.5 and 6.25 μg/animal) were in-
jected into the wing vein of 10-day-old chicks. After 60 min, the 
animals were anesthetized and bled for analysis of serum calcium by 
means of atomic absorption spectroscopy (Atomic Absorption Spec-
trometer M 2100, Perkin Elmer, Munich, Germany). 
3 . Results and discussion 
Parathyroid hormone is rapidly metabolized, mainly by the 
liver and kidney, to smaller peptides of mostly unknown bio-
logical activity. Generation of circulating biologically active 
N-terminal P T H has been suggested on the basis of certain 
observations in vitro [20,21], and what are believed to be N -
terminal fragments may be detectable in blood under pa tho-
logical circumstances in vivo [3]. The determination of N -
terminal fragments of P T H in the blood was carried out using 
immunological [22,23] and chromatographic methods (such as 
retention time) [24], or a combination of bo th [25]. These 
methods, however, do not allow a definitive conclusion about 
the exact molecular form which is characterized by a distinct 
molecular weight and related amino acid sequence. 
Taking the above findings into account, we started an ex-
traction procedure with a readily accessible equivalent of hu-
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Fig. 3. Epitope mapping of the polyclonal antibody was used for the affinity chromatography. 
man plasma, namely hemofiltrate, which contains mostly plas-
ma peptides < 20 000 Da. This starting material was first 
treated by ion-exchange absorption on alginic acid in organic 
and aqueous solution (step 1) and elution of the crude peptide 
extract. Affinity chromatography (step 2) and two reverse-
phase HPLC separations on C4 and C18 supports (steps 3 
and 4) yielded a purification to identify the N-terminal 
hPTH molecular form. Aliquots from the analytical RP sep-
aration (Fig. 1) were measured by means of IEMA (Fig. 2) 
to detect the N-terminal parathyroid hormone [18]. This assay 
detects hPTH-1-84 and fragments of this peptide if the N-
terminus is intact (Fig. 3). The main activity eluted in fraction 
24 which was found to be a bioactive (Fig. 4) 4404 Da (Figs. 5 
and 6) peptide. The remaining activity corresponded to the 
intact hPTH-1-84 on this RP HPLC column. 
These findings are in general agreement with those reported 
by Schettler et al. [26] who analyzed N-terminal hPTH frag-
ments by means of RP HPLC and RIA from human plasma 
extracts from healthy individuals, osteoporotic, hyperpar-
athyroid, and pseudohyperparathyroid patients. The pattern 
of the different fragments was considered to be disease-specific 
in their proportion. One peak eluting consistently in all cases 
was supposed to represent hPTH-1-38 [26]. The results ob-
tained in the present study are in agreement with those of 
earlier investigations of our group [12] demonstrating the oc-
currence of two C-terminal fragments, hPTH-38-84 and 
hPTH-38-54 in hemofiltrate which clearly demonstrate the 
crucial cleavage site to result in hPTH-1-37 at the N-terminal 
portion. The possibility of an enzymatic cleavage of hPTH-1-
84 was investigated by Botti et al. [27] using acid endopepti-
dase of a kidney cortex plasma membrane preparation. This 
cleavage obtained by a bovine endopeptidase of the kidney 
may, however, not represent a metabolic pathway leading to 
the circulating hPTH form. In their experiments, hydrolysis of 
PTH-1-84 generated accumulating levels of C-terminal frag-
ments comprising the residues 35 and 38 as demonstrated by 
microsequencing the cleaved fragments. However, Bringhurst 
et al. [28] were able to demonstrate the in vivo existence of N-
terminal bioactive bPTH fragments. Nevertheless, these 
authors concluded that a cleavage may occur in position 
30-35 of intact PTH-1-84 by endopeptidases of the liver 
and kidney, generating both N- and C-terminal fragments, 
with the N-terminal fragment(s) tending to accumulate in 
the kidneys. In this context, it should be emphasized that 
hemofiltrate from patients with chronic renal failure was 
used in our experiments, i.e. impaired renal clearance of 
PTH fragments as a cause of higher endogenous levels is likely 
to occur [29]. 
To check for the generation of artefacts during storage and 
purification of the hemofiltrate, hPTH-1-84 and N-terminal 
fragments 1-32 to 1-38 (except for 1-36) were added to he-
mofiltrate for 24 h. There was no degradation of the tested 
peptides, as judged by RP HPLC. In view of the considerable 
loss of material due to the hydrophobicity of hPTH-1-37, it is 
not possible to estimate the physiological plasma concentra-
Ca - serum concentration after Lv. injection of hPTH-1-37 
dose ^ g hPTH-l-37/chick) 
Fig. 4. Biological activity of hPTH-1-37 (1.0, 2.5 and 6.25 μ^αηί-
mal) after intravenous injection into a chick. Changes in Ca plasma 
concentration were measured (atomic absorption spectroscopy) 1 h 
after administration. Values are given as mean ± SEM, n = 6. 
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Fig. 5. LC-MS of immunoreactive fraction 24, using a microbore RP-Cig column (YMC, 250 X 1 mm ID) and a Sciex API-Ill ion-spray mass 
detector. The prominent ion at m/z 1101 is charged fourfold. 
tions of this peptide in vivo. Bringhurst et al. [28] investigated 
the fate of N-terminal fragments. Using bovine [35S]PTH-l-84 
in combination with high resolution chromatographic techni-
ques sensitive to 10~13 M PTH peptides, there was no evi-
dence of generation of circulating N-terminal PTH fragments. 
It was shown that the N-terminal end of PTH was rapidly 
degraded in situ by the liver, but that both liver and kidneys 
nevertheless contained low levels of N-terminal fragments. It 
was concluded that the peripheral metabolism of PTH in nor-
mal rats does not lead to circulating N-terminal fragments of 
the hormone. In this study, however, bovine PTH was used 
and the tests were carried out in rats, being a heterologous 
species. Similarly, a number of studies designed to clarify the 
metabolic fate of hPTH-1-84 [10,30-35] were performed in 
heterologous systems which may inherently result in unnatural 
metabolic kinetics. 
From the literature available so far it may be postulated 
that hPTH-1-37 is cleaved to hPTH-1-34. This hypothesis 
was, however, not confirmed by our findings since we could 
not identify any fragment which may relate to hPTH-1-34. 
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